Lesson plan

NH130

NH130 is a highly selective serotonin 5-HT 2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis. It is taken orally. The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours. NH130 is under development by Jiangsu Nhwa Pharmaceutical in China. As of November 2025, it is in phase 2 clinical trials.

Back to article

Article summary

NH130 is a highly selective serotonin 5-HT 2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis. It is taken orally. The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours. NH130 is under development by Jiangsu Nhwa Pharmaceutical in China. As of November 2025, it is in phase 2 clinical trials.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.